LY-2940094
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| Synonyms | BTRX-246040 |
| CAS Number | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H23ClF2N4O2S |
| Molar mass | 480.96 g·mol−1 |
| 3D model (Jmol) | |
|
|
|
|
LY-2940094, also known as BTRX-246040, is a potent and selective nociceptin receptor antagonist which is under investigation by Eli Lilly for the treatment of major depressive disorder (MDD) and alcohol dependence.[1][2] It has demonstrated proof-of-concept clinical efficacy for depression.[3] As of 2015, it is in phase II clinical trials for both of the aforementioned indications.[1][2] However, it has more recently been reported that development for these indications has been discontinued and that the drug is now under development instead for the treatment of neurological disorders.[4]
See also[edit]
References[edit]
- ^ a b Dale, Elena; Bang-Andersen, Benny; Sánchez, Connie (2015). "Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs" (PDF). Biochemical Pharmacology. 95 (2): 81–97. ISSN 0006-2952. PMID 25813654. doi:10.1016/j.bcp.2015.03.011.
- ^ a b Yin, Xin; Guven, Nuri; Dietis, Nikolas (2015). "Opioids in Depression: Not Quite There Yet" (PDF). UK Journal of Pharmaceutical and Biosciences. 3 (1): 12–17.
- ^ Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM (2015). "A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies". Neuropsychopharmacology. PMID 26585287. doi:10.1038/npp.2015.348.
- ^ http://adisinsight.springer.com/drugs/800033400
External links[edit]
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
